James T. Symanowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James T. Symanowski has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Aynur Aktas
Department of Supportive Oncology Levine Cancer Institute, Atrium Health Charlotte North Carolina USA
2 shared publications - Declan Walsh
Levin Cancer, Atrium Health Levine Cancer Institute, Charlotte, North Carolina, USA
2 shared publications - Jonathan C. Salo
Levine Cancer Institute, Atrium Health, Charlotte, USA
2 shared publications - Kunal C. Kadakia
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, NC
2 shared publications - Michele L. Szafranski
Section of Oncology Nutrition, Department of Supportive Oncology, Atrium Health Levine Cancer , Charlotte, USA
2 shared publications - Adilen Cruz
Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC
1 shared publication
Latest Publications
- 15 January 2025
- Published by BMJ in BMJ Supportive & Palliative Care
Malnutrition risk and overall survival at solid tumour diagnosis
Purpose Malnutrition severely impacts tolerance to anticancer therapies, but any relationship with overall survival (OS) at the time of solid tumour diagnosis in outpatients in the USA remains unclear. Methods This retrospective study evaluated 3562 patients who completed the Malnutrition Screening Tool (MST) at diagnosis, identifying the relationship between MST risk, a validated tool evaluating anorexia and weight loss, and OS. MST score of ≥2 of 5 was classified as high malnutrition risk (H-MST). Kaplan-Meier techniques and Cox proportional hazards models were used to analyse OS in H-MST versus low malnutrition risk (L-MST). Results In the unadjusted models, MST risk was individually associated with OS. Multivariable regression confirmed that MST risk remained independently prognostic for OS after controlling for key confounding variables, HR=1.51 (95% CI: 1.33 to 1.72). The H-MST group had shorter OS (50-month survival rates: 69% L-MST vs 60% H-MST). Conclusion MST risk at diagnosis is an independent prognostic factor for OS. H-MST risk is associated with shorter survival in a broad cohort of solid tumour oncology outpatients.
- 15 January 2025
- Published by BMJ in BMJ Supportive & Palliative Care
Malnutrition risk and overall survival at solid tumour diagnosis
Purpose Malnutrition severely impacts tolerance to anticancer therapies, but any relationship with overall survival (OS) at the time of solid tumour diagnosis in outpatients in the USA remains unclear. Methods This retrospective study evaluated 3562 patients who completed the Malnutrition Screening Tool (MST) at diagnosis, identifying the relationship between MST risk, a validated tool evaluating anorexia and weight loss, and OS. MST score of ≥2 of 5 was classified as high malnutrition risk (H-MST). Kaplan-Meier techniques and Cox proportional hazards models were used to analyse OS in H-MST versus low malnutrition risk (L-MST). Results In the unadjusted models, MST risk was individually associated with OS. Multivariable regression confirmed that MST risk remained independently prognostic for OS after controlling for key confounding variables, HR=1.51 (95% CI: 1.33 to 1.72). The H-MST group had shorter OS (50-month survival rates: 69% L-MST vs 60% H-MST). Conclusion MST risk at diagnosis is an independent prognostic factor for OS. H-MST risk is associated with shorter survival in a broad cohort of solid tumour oncology outpatients.
- Open Access
- 24 May 2024
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 282 (6) , 998-1006
A Randomized, Single-Center, Superiority Trial of Radioactive Seed Localization Versus Wire Localization for Malignant Breast Disease
Objective: Compare radioactive seed localization (RSL) and wire-guided localization (WL) for nonpalpable malignant breast disease. Background: While WL has been the most common approach for localization of nonpalpable breast tumors, other techniques such as RSL, intraoperative ultrasound, radioactive intraoperative occult lesion localization, hematoma localization, radar localization, and magnetic seed localization have been suggested as safe and efficacious alternatives. However, very few randomized controlled trials have compared these localization techniques. Methods: Between July 2015 and January 2021, 400 women with nonpalpable malignant breast disease were randomized 1:1 to RSL or WL, stratified by the surgeon and invasive disease status. The primary outcome was initial resection negative margin rates. Secondary outcomes included time efficiencies, cost, and satisfaction. Results: There was no significant difference in negative margin rates between RSL and WL [RSL 0.80 (95% CI: 0.75–0.86) vs WL 0.85 (95% CI: 0.80–0.89); P =0.29]. RSL received better patient scores for anxiety [OR=2.62 (95% CI: 1.79–3.84); P P P P P =0.02]. Time in radiology did not differ [RSL mean (SD) 12.8±9.5 min vs. WL 11.4±6.0 min; P =0.18]. RSL incurred a $600 higher cost than WL. Conclusions: The results of the largest randomized controlled trial in the United States support RSL as an acceptable alternative to WL in the treatment of nonpalpable malignant breast disease. While RSL was not superior to WL in achievement of negative margins, patients and providers reported improved satisfaction scores.
- 24 May 2024
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 282 (6) , 998-1006
Open AccessA Randomized, Single-Center, Superiority Trial of Radioactive Seed Localization Versus Wire Localization for Malignant Breast Disease
Objective: Compare radioactive seed localization (RSL) and wire-guided localization (WL) for nonpalpable malignant breast disease. Background: While WL has been the most common approach for localization of nonpalpable breast tumors, other techniques such as RSL, intraoperative ultrasound, radioactive intraoperative occult lesion localization, hematoma localization, radar localization, and magnetic seed localization have been suggested as safe and efficacious alternatives. However, very few randomized controlled trials have compared these localization techniques. Methods: Between July 2015 and January 2021, 400 women with nonpalpable malignant breast disease were randomized 1:1 to RSL or WL, stratified by the surgeon and invasive disease status. The primary outcome was initial resection negative margin rates. Secondary outcomes included time efficiencies, cost, and satisfaction. Results: There was no significant difference in negative margin rates between RSL and WL [RSL 0.80 (95% CI: 0.75–0.86) vs WL 0.85 (95% CI: 0.80–0.89); P =0.29]. RSL received better patient scores for anxiety [OR=2.62 (95% CI: 1.79–3.84); P P P P P =0.02]. Time in radiology did not differ [RSL mean (SD) 12.8±9.5 min vs. WL 11.4±6.0 min; P =0.18]. RSL incurred a $600 higher cost than WL. Conclusions: The results of the largest randomized controlled trial in the United States support RSL as an acceptable alternative to WL in the treatment of nonpalpable malignant breast disease. While RSL was not superior to WL in achievement of negative margins, patients and providers reported improved satisfaction scores.
- 28 October 2021
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (3) , 2237-2244
Malnutrition risk at solid tumor diagnosis: the malnutrition screening tool in a large US cancer institute
Background In cancer, malnutrition is common and negatively impacts tolerance and outcomes of anti-tumor therapies. The aim of this study was to evaluate the prevalence of malnutrition risk and compare the clinicodemographic features between those with high malnutrition screening tool (MST) scores (i.e., ≥ 2 of 5 = high risk for malnutrition, H-MST) to low scores (L-MST). Methods A cohort of 3585 patients (May 2017 through December 2018), who completed the MST at least once at the time of diagnosis of any stage solid tumor, were analyzed. Logistic regression tested for associations between clinicodemographic factors, symptom scores, and H-MST prevalence. Results The median age was 64 years (25–75 IQR, 55–72), with 62% females and 81% White. Most common tumor primary sites were breast (28%), gastrointestinal (GI) (21%), and thoracic (13%). Most had non-metastatic disease (80%). H-MST was found in 28%—most commonly in upper (58%) and lower GI (42%), and thoracic (42%) tumors. L-MST was most common in breast (90%). Multivariable regression confirmed that Black race (OR 1.9, 95% CI 1.5–2.4, p = < 0.001), cancer primary site (OR 1.6–5.7, p = < 0.001), stage IV disease (OR 1.8, 95% CI 1.4–2.2, p = < 0.001), low BMI (OR 4.2, 95% CI 2.5–6.9 p = < 0.001), and higher symptom scores were all independently associated with H-MST. Conclusions Twenty-eight percent of solid tumor oncology patients at diagnosis were at high risk of malnutrition. Patients with breast cancer rarely had malnutrition risk at diagnosis. Significant variation was found in malnutrition risk by cancer site, stage, race, and presence of depression, distress, fatigue, and trouble eating/swallowing.
- 28 October 2021
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (3) , 2237-2244
Malnutrition risk at solid tumor diagnosis: the malnutrition screening tool in a large US cancer institute
Background In cancer, malnutrition is common and negatively impacts tolerance and outcomes of anti-tumor therapies. The aim of this study was to evaluate the prevalence of malnutrition risk and compare the clinicodemographic features between those with high malnutrition screening tool (MST) scores (i.e., ≥ 2 of 5 = high risk for malnutrition, H-MST) to low scores (L-MST). Methods A cohort of 3585 patients (May 2017 through December 2018), who completed the MST at least once at the time of diagnosis of any stage solid tumor, were analyzed. Logistic regression tested for associations between clinicodemographic factors, symptom scores, and H-MST prevalence. Results The median age was 64 years (25–75 IQR, 55–72), with 62% females and 81% White. Most common tumor primary sites were breast (28%), gastrointestinal (GI) (21%), and thoracic (13%). Most had non-metastatic disease (80%). H-MST was found in 28%—most commonly in upper (58%) and lower GI (42%), and thoracic (42%) tumors. L-MST was most common in breast (90%). Multivariable regression confirmed that Black race (OR 1.9, 95% CI 1.5–2.4, p = < 0.001), cancer primary site (OR 1.6–5.7, p = < 0.001), stage IV disease (OR 1.8, 95% CI 1.4–2.2, p = < 0.001), low BMI (OR 4.2, 95% CI 2.5–6.9 p = < 0.001), and higher symptom scores were all independently associated with H-MST. Conclusions Twenty-eight percent of solid tumor oncology patients at diagnosis were at high risk of malnutrition. Patients with breast cancer rarely had malnutrition risk at diagnosis. Significant variation was found in malnutrition risk by cancer site, stage, race, and presence of depression, distress, fatigue, and trouble eating/swallowing.